This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…
Phase: PHASE1 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC